Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs
"We are benefiting from very significant growth of the GLP-1 class," said Conterno, president of Lilly Diabetes and Lilly USA, at the UBS Global Healthcare Conference in New York. "And in fact, as we see additional competitors, they are further fueling ...
Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns
Enrique Conterno, president of Lilly Diabetes and Lilly USA, said on an earnings call Wednesday that "we continue to see pressure on pricing across all of our diabetes products." "When we look at our Q4 results, I think there was pressure from a ...
Global Non-Insulin Therapies for Diabetes Market 2018- GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia ...
The market study on Global Non-Insulin Therapies for Diabetes Market 2018 Research Report studies current as well as future aspects of the Non-Insulin Therapies for Diabetes Market primarily based upon factors on which the companies compete in theĀ ...